Novo Holdings A/S - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Role: 10%+ Owner
Signature: /s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
Issuer symbol: N/A
Transactions as of: 17 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 17 Jun 2021, 21:43:24 UTC
Previous filing: 16 Jun 2021
Next filing: 22 Jun 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CYT	SERIES B CONVERTIBLE PREFERRED STOCK							17 Jun 2021	COMMON STOCK	4,107,017		Direct	F1
holding	CYT	SERIES C CONVERTIBLE PREFERRED STOCK							17 Jun 2021	COMMON STOCK	455,619		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will convert automatically into shares of common stock based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. The securities shown in Column 3 give effect to the conversion ratio.

Content

Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will convert automatically into shares of common stock based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. The securities shown in Column 3 give effect to the conversion ratio.